Background: Drug delivery systems such as hydrogels have become relevant
in cardiovascular and metabolic therapies due to their sustained and controlled release
properties of drugs, versatile polymer structures, safety, and biodegradability.
Results: The literature presented demonstrates that a hydrogel-based controlled release
system increases the therapeutic efficacy in different components of the metabolic syndrome.
Hypertension has been the most explored component with advances in in vitro
and murine models. However, clinical evidence in humans is scarce, and more translational
studies are needed. Hydrogel-based systems for diabetes, obesity, and dyslipidemia
have been little explored. Observations mainly demonstrated an increase in therapeutic efficacy,
in vitro and in vivo, for the use of insulin, leptin, and natural components, such as
epigallocatechin gallate. In all cases, the hydrogel systems achieve better plasma levels
of the loaded compound, higher bioavailability, and low cytotoxicity compared to conventional
systems. Also, the evidence existing suggests that the development of an injectable
hydrogel system for controlled release of drugs or therapeutic compounds is presented
as an attractive option for MeS treatment, and due to the possibility of sustained
pharmacological release, there is no need for repeated doses and a safe administration
Conclusion: The following review aims to evaluate the use of the hydrogel systems in
the therapy of diabetes, obesity, hypertension, and dyslipidemia, which are the main components
of metabolic syndrome.